Proprietary AI analyst is now available

InfuSystem Valuation Multiples

Discover revenue and EBITDA valuation multiples for InfuSystem and similar public comparables like Deltex Medical Group, Apyx Medical, Quanterix, Surgical Science and more.

InfuSystem Overview

About InfuSystem

InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-reportable segment. The first is Patient Services, providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The Patient segment is comprised of Oncology, Pain Management and Wound Therapy businesses. The second, Device Solutions, supports the Patient Services platform and leverages service orientation to win incremental business from its direct payer clients. The Device segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair. Majority from Patient.


Founded

2005

HQ

United States

Employees

514

Financials (LTM)

Revenue: $144M
EBITDA: $32M

EV

$205M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

InfuSystem Financials

InfuSystem reported last 12-month revenue of $144M and EBITDA of $32M.

In the same LTM period, InfuSystem generated $81M in gross profit, $32M in EBITDA, and $8M in net income.

Revenue (LTM)


InfuSystem P&L

In the most recent fiscal year, InfuSystem reported revenue of $143M and EBITDA of $31M.

InfuSystem is profitable as of last fiscal year, with gross margin of 56%, EBITDA margin of 22%, and net margin of 5%.

See analyst estimates for InfuSystem
LTMLast FY202320242025202620272028
Revenue$144M$143M$126M$135M$143M
Gross Profit$81M$80M$63M$70M$80M
Gross Margin56%56%50%52%56%
EBITDA$32M$31M$17M$19M$25M
EBITDA Margin22%22%13%14%18%
EBIT Margin9%8%3%5%8%
Net Profit$8M$7M$872K$2M$7M
Net Margin5%5%1%2%5%
Net Debt-$16M---

Financial data powered by Morningstar, Inc.

InfuSystem Stock Performance

InfuSystem has current market cap of $184M, and enterprise value of $205M.

Market Cap Evolution


InfuSystem's stock price is $9.12.

InfuSystem share price increased by 0.6% in the last 30 days, and by 46.2% in the last year.

InfuSystem has an EPS (earnings per share) of $0.33.

See more trading valuation data for InfuSystem
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$205M$184M1.0%0.6%-1.2%46.2%$0.33

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

InfuSystem Valuation Multiples

InfuSystem trades at 1.4x EV/Revenue multiple, and 6.4x EV/EBITDA.

See NTM and 2027E valuation multiples for InfuSystem

EV / Revenue (LTM)


InfuSystem Financial Valuation Multiples

As of June 5, 2026, InfuSystem has market cap of $184M and EV of $205M.

InfuSystem has a P/E ratio of 24.1x.

LTMLast FY202320242025202620272028
EV/Revenue1.4x1.4x1.6x1.5x1.4x
EV/EBITDA6.4x6.5x12.4x10.6x8.1x
EV/EBIT16.2x17.2x50.1x29.7x17.2x
EV/Gross Profit2.5x2.5x3.2x2.9x2.5x
P/E24.1x27.8x211.1x78.5x27.8x
EV/FCF-13.0xn/m78.0x13.0x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified InfuSystem Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

InfuSystem Margins & Growth Rates

InfuSystem grew revenue by 1% and EBITDA by 4% in the last fiscal year.

In the most recent fiscal year, InfuSystem reported gross margin of 56%, EBITDA margin of 22%, and net margin of 5%.

See estimated margins and future growth rates for InfuSystem

InfuSystem Margins

Last FY202420252026202720282029
Gross Margin56%52%56%57%
EBITDA Margin22%14%18%22%
EBIT Margin8%5%8%9%
Net Margin5%2%5%6%
FCF Margin11%2%11%-

InfuSystem Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth1%7%6%1%
Gross Profit Growth3%12%14%3%
EBITDA Growth4%17%30%29%
EBIT Growth14%69%73%14%
Net Profit Growth36%169%183%36%
FCF Growth-2377%499%-

Data powered by FactSet, Inc. and Morningstar, Inc.

InfuSystem Operational KPIs

InfuSystem's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.

InfuSystem's Rule of 40 is 23% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

InfuSystem's Rule of X is 25% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for InfuSystem
LTMLast FY202320242025202620272028
Rule of 4026%23%---
Bessemer Rule of X32%25%---
Revenue per Employee-$0.3M---
Opex per Employee-$0.1M---
S&M Expenses to Revenue8%7%10%8%7%
G&A Expenses to Revenue39%40%36%38%40%
Opex to Revenue-48%47%47%48%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

InfuSystem Competitors

InfuSystem competitors include Deltex Medical Group, Apyx Medical, Quanterix, Surgical Science, Lucid Diagnostics, Ilex Medical, Inogen, Anika Therapeutics, Asterasys and Viromed Medical.

Most InfuSystem public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Deltex Medical Group----
Apyx Medical3.6x3.4x(49.4x)(48.0x)
Quanterix0.8x0.8x(2.6x)(3.1x)
Surgical Science1.1x1.1x6.0x6.5x
Lucid Diagnostics43.1x34.7x(3.6x)(3.9x)
Ilex Medical0.4x-3.1x-
Inogen0.2x0.2x28.9x27.3x
Anika Therapeutics1.6x1.6x34.0x24.7x

This data is available for Pro users. Sign up to see all InfuSystem competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About InfuSystem

When was InfuSystem founded?InfuSystem was founded in 2005.
Where is InfuSystem headquartered?InfuSystem is headquartered in United States.
How many employees does InfuSystem have?As of today, InfuSystem has over 514 employees.
Who is the CEO of InfuSystem?InfuSystem's CEO is Carrie A. Lachance.
Is InfuSystem publicly listed?Yes, InfuSystem is a public company listed on NYSE American.
What is the stock symbol of InfuSystem?InfuSystem trades under INFU ticker.
When did InfuSystem go public?InfuSystem went public in 1992.
Who are competitors of InfuSystem?InfuSystem main competitors include Deltex Medical Group, Apyx Medical, Quanterix, Surgical Science, Lucid Diagnostics, Ilex Medical, Inogen, Anika Therapeutics, Asterasys, Viromed Medical.
What is the current market cap of InfuSystem?InfuSystem's current market cap is $184M.
What is the current revenue of InfuSystem?InfuSystem's last 12 months revenue is $144M.
What is the current revenue growth of InfuSystem?InfuSystem revenue growth (NTM/LTM) is 4%.
What is the current EV/Revenue multiple of InfuSystem?Current revenue multiple of InfuSystem is 1.4x.
What is the current EBITDA of InfuSystem?InfuSystem's last 12 months EBITDA is $32M.
What is InfuSystem's EBITDA margin?InfuSystem's last 12 months EBITDA margin is 22%.
What is the current EV/EBITDA multiple of InfuSystem?Current EBITDA multiple of InfuSystem is 6.4x.
How many companies InfuSystem has acquired to date?InfuSystem hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies InfuSystem has invested to date?InfuSystem hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to InfuSystem

Lists including InfuSystem

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial